Close menu




March 28th, 2024 | 08:45 CET

TUI, dynaCERT, Evotec - The profit is in buying

  • Hydrogen
  • greenhydrogen
  • travel
  • Biotechnology
Photo credits: pixabay.com

In the world of the financial markets, the timeless maxim applies: "The profit is in buying". This tried and tested stock market adage, which may seem trivial at first glance, is actually the key to financial success. Indeed, the price at which an investment is purchased often determines its subsequent triumph or failure long before the sale is even considered. Despite advances in technology and the complexity of markets, the basic lesson remains - buying wisely and at a well-considered price lays the foundation for profits. We have picked out three interesting candidates.

time to read: 4 minutes | Author: Armin Schulz
ISIN: DYNACERT INC. | CA26780A1084 , TUI AG NA O.N. | DE000TUAG505 , EVOTEC SE INH O.N. | DE0005664809

Table of contents:


    Jim Payne, CEO, dynaCERT Inc.
    "[...] We are committed to stay as the number one Canadian and global leader in the Hydrogen-On-Demand diesel technology [...]" Jim Payne, CEO, dynaCERT Inc.

    Full interview

     

    TUI - Prospects are visibly improving

    Given a growing desire to travel, TUI, Europe's No. 1 travel provider, is facing a promising year. The Company's management, represented by CEO Sebastian Ebel, is optimistic, particularly regarding popular destinations such as Majorca, which is expected to welcome millions of German vacationers. The German travel market has had a strong start to the year, indicated by an increase in overnight stays, and appears to be heading for another record year, almost on par with the pre-pandemic year, 2019. The global tourism economy is also showing signs of recovery and could soon return to pre-pandemic figures.

    To appeal to even more customers in the future, the Company is using artificial intelligence to improve the booking process. Following a successful pilot project in the UK, TUI now intends to make greater use of the technology. In addition, the Group has published internal guidelines on the use of artificial intelligence, which focus on employee qualification, comprehensive training and ethical considerations. In terms of expansion, TUI is focusing on the DACH region and plans to open new hotels. These innovations are intended to strengthen the hotel portfolio on the one hand and to appeal to a target group of young, high-earning individuals on the other.

    Despite these positive signs, the TUI share has only improved slightly. Turnover in the sector is showing stronger momentum, for example, due to longer lengths of stay and growing demand for upscale hotel categories. Accordingly, the outlook for the share is positive. This is also the view of the analysts at Morgan Stanley, who have issued a "Buy" recommendation with a target price of EUR 10.00. From a technical perspective, the share exceeded the important EUR 7.50 mark on Tuesday, which could generate upward momentum. The share is currently trading at EUR 7.52.

    dynaCERT - Revolutionizing diesel engines with hydrogen technology

    Every year, millions of diesel engines are produced worldwide, of which more than one billion are currently in operation in various sectors such as transportation, shipping, construction and power generation. The problem is the emissions from these engines for the environment. With its HydraGEN™ technology, dynaCERT has made it possible to reduce these emissions. Using an innovative electrolysis unit, distilled water is converted into hydrogen and oxygen gases on demand, improving combustion efficiency in diesel engines. In addition to reducing emissions, less fuel is consumed.

    HydraLytica™ software collects data on the vehicles with the integrated HydraGEN™ technology. These fuel savings and greenhouse gas reductions are used to generate data for potential emission credits. These CO2 certificates are to be issued by Verra. Work on this has been ongoing for some time but has now reached the final stage. At the end of November, Earthood Services delivered the last missing report for Verra. The Verra website now also shows that the dynaCERT technology is in the "Final Verra Review" phase. So it cannot be long now until dynaCERT gets the green light.

    This would be a milestone for both customers and dynaCERT. Customers could use the carbon credits generated as an advertising opportunity as their carbon footprint improves - dynaCERT shares the carbon credits with customers, generating recurring revenue. In addition to the HydraGEN™ system, the Company is also involved in Cipher Neutron. It is a cleantech company that focuses on producing low-cost green hydrogen using AEM electrolyser technology. Further information can be found in the presentation by CEO Jim Payne from the 10th International Investment Forum that took place in February. The share is currently trading at CAD 0.15.

    Evotec - Candidate for a takeover?

    Evotec is characterized by global development partnerships and is positively highlighted by analysts for its broad project pipeline and the potential for future pharmaceutical successes. With the expectation to increase revenues to EUR 1 billion and adjusted operating profit to at least EUR 300 million by 2025, the Company is looking ahead to further innovative breakthroughs in drug development. The unexpected resignation of the former CEO, Werner Lanthaler, should no longer play a role in the future, even if it is responsible for the share price crash.

    Last month, the Company reported three pieces of positive news. The first was a framework agreement between Evotec and Claris Ventures to accelerate the programs of Claris' portfolio companies into the clinical phase using Evotec's platform. On March 14, Tubulis closed a EUR 128 million financing to accelerate the clinical development of its solid tumor ADC pipelines. Evotec indirectly benefits from this through its strategic partnership with Bristol Myers Squibb, which is responsible for the development and commercialization of the antibody-drug conjugates.

    Then, Evotec's spin-off Breakpoint Therapeutics GmbH announced that BTX-011, a promising polymerase theta inhibitor, has been nominated as the first preclinical development candidate for the treatment of solid tumors and that IND-preparatory activities have started. The share has not yet experienced any real upswing. With a market capitalization of around EUR 2.4 billion and a share price of EUR 13.79, the share could become a takeover target. There have recently been a number of takeovers in the biotech sector.


    All three companies presented appear favorable in the current environment. The TUI share has not yet been able to participate in the general industry recovery and has some catching up to do. dynaCERT would achieve the big hit with the Verra certification, and the share would have to be revalued immediately. Evotec has come under pressure due to the resignation of the CEO, but operations are going well, and so are the prospects. The share price should rise if the Company becomes a takeover target.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a "Transaction"). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
    In this respect, there is a concrete conflict of interest in the reporting on the companies.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
    For this reason, there is also a concrete conflict of interest.
    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author



    Related comments:

    Commented by Fabian Lorenz on April 16th, 2024 | 07:55 CEST

    Drumbeat at TUI! Caution with Renk and Nel! dynaCERT Stock with Potential!

    • Hydrogen
    • Travel
    • Defense
    • armaments

    A drumbeat is sounding at TUI! In an interview, the tourism group's CFO hints that shareholders can soon look forward to a dividend again. On the other hand, tensions in the Middle East are causing short-term uncertainty in tourism shares. Conversely, defense stocks are once again benefiting from the possibility of an escalation. However, analysts currently see little further potential for Renk. The retrofit kits from dynaCERT offer great potential for reducing emissions from diesel vehicles. If VERRA clears the way for CO2 certificates, the share could go through the roof. Is the Company preparing for this with a personnel change? In contrast, the Nel share seeks support, and tomorrow promises to be exciting.

    Read

    Commented by Stefan Feulner on April 16th, 2024 | 07:40 CEST

    Formycon, Defence Therapeutics, Morphosys - Significant movement in the biotech sector

    • Biotechnology
    • Pharma
    • Cancer

    At the moment, investors are focusing on gold and Bitcoin in addition to the most important indices, like the DAX and Dow Jones. Meanwhile, the biotechnology sector is barely mentioned in the local newspapers. However, the market is on the move, and the wave of takeovers continues unabated. Recently, the Danish pharmaceutical company Genmab announced it was acquiring the private biotech company ProfoundBio for USD 1.8 billion in cash. The acquisition is intended to help deepen the cancer pipeline with next-generation antibody-drug conjugate therapies. Big Pharma is likely to make further acquisitions in this area in the near future.

    Read

    Commented by Fabian Lorenz on April 16th, 2024 | 07:20 CEST

    Plug Power deeply in the red! Thyssenkrupp Nucera and First Hydrogen shares with positive newsflow and upside potential!

    • Hydrogen
    • greenhydrogen
    • GreenTech
    • renewableenergies

    Not only is Plug Power's share price in the red, but also its earnings for the year 2023. Losses at the US company are still growing faster than revenue. Together with its struggling industry peer, Nel ASA, Plug is dragging down the entire hydrogen sector. However, there are positive developments. For example, the hydrogen-powered fuel cell commercial vehicle from First Hydrogen in England has impressed in test drives under real conditions. The Company is currently valued at only CAD 50 million and offers an entry opportunity. Analysts also see more than 100% upside potential for Thyssekrupp Nucera. Is the wheat separating from the chaff in the hydrogen sector?

    Read